Italy · Delayed Price · Currency is EUR Pharmanutra Statistics
Total Valuation
Pharmanutra has a market cap or net worth of EUR 691.33 million. The enterprise value is 694.55 million.
| Market Cap | 691.33M |
| Enterprise Value | 694.55M |
Important Dates
The next estimated earnings date is Tuesday, November 10, 2026.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | May 4, 2026 |
Share Statistics
Pharmanutra has 9.58 million shares outstanding. The number of shares has decreased by -0.12% in one year.
| Current Share Class | 9.58M |
| Shares Outstanding | 9.58M |
| Shares Change (YoY) | -0.12% |
| Shares Change (QoQ) | -0.52% |
| Owned by Insiders (%) | 65.81% |
| Owned by Institutions (%) | 9.61% |
| Float | 3.27M |
Valuation Ratios
The trailing PE ratio is 33.35 and the forward PE ratio is 25.36.
| PE Ratio | 33.35 |
| Forward PE | 25.36 |
| PS Ratio | 4.81 |
| PB Ratio | 9.94 |
| P/TBV Ratio | 15.44 |
| P/FCF Ratio | 46.02 |
| P/OCF Ratio | 36.24 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.57, with an EV/FCF ratio of 46.23.
| EV / Earnings | 33.48 |
| EV / Sales | 4.83 |
| EV / EBITDA | 20.57 |
| EV / EBIT | 22.67 |
| EV / FCF | 46.23 |
Financial Position
The company has a current ratio of 2.05, with a Debt / Equity ratio of 0.26.
| Current Ratio | 2.05 |
| Quick Ratio | 1.51 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | 0.54 |
| Debt / FCF | 1.22 |
| Interest Coverage | 54.82 |
Financial Efficiency
Return on equity (ROE) is 31.60% and return on invested capital (ROIC) is 29.78%.
| Return on Equity (ROE) | 31.60% |
| Return on Assets (ROA) | 16.19% |
| Return on Invested Capital (ROIC) | 29.78% |
| Return on Capital Employed (ROCE) | 35.22% |
| Weighted Average Cost of Capital (WACC) | 5.06% |
| Revenue Per Employee | 997,903 |
| Profits Per Employee | 144,056 |
| Employee Count | 144 |
| Asset Turnover | 1.21 |
| Inventory Turnover | 7.46 |
Taxes
In the past 12 months, Pharmanutra has paid 10.31 million in taxes.
| Income Tax | 10.31M |
| Effective Tax Rate | 33.28% |
Stock Price Statistics
The stock price has increased by +76.74% in the last 52 weeks. The beta is 0.16, so Pharmanutra's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | +76.74% |
| 50-Day Moving Average | 80.64 |
| 200-Day Moving Average | 76.00 |
| Relative Strength Index (RSI) | 36.17 |
| Average Volume (20 Days) | 23,047 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmanutra had revenue of EUR 143.70 million and earned 20.74 million in profits. Earnings per share was 2.17.
| Revenue | 143.70M |
| Gross Profit | 72.27M |
| Operating Income | 30.64M |
| Pretax Income | 30.97M |
| Net Income | 20.74M |
| EBITDA | 33.20M |
| EBIT | 30.64M |
| Earnings Per Share (EPS) | 2.17 |
Balance Sheet
The company has 15.14 million in cash and 18.36 million in debt, with a net cash position of -3.22 million or -0.34 per share.
| Cash & Cash Equivalents | 15.14M |
| Total Debt | 18.36M |
| Net Cash | -3.22M |
| Net Cash Per Share | -0.34 |
| Equity (Book Value) | 69.53M |
| Book Value Per Share | 7.26 |
| Working Capital | 35.52M |
Cash Flow
In the last 12 months, operating cash flow was 19.08 million and capital expenditures -4.05 million, giving a free cash flow of 15.02 million.
| Operating Cash Flow | 19.08M |
| Capital Expenditures | -4.05M |
| Depreciation & Amortization | 2.56M |
| Net Borrowing | -3.77M |
| Free Cash Flow | 15.02M |
| FCF Per Share | 1.57 |
Margins
Gross margin is 50.29%, with operating and profit margins of 21.32% and 14.44%.
| Gross Margin | 50.29% |
| Operating Margin | 21.32% |
| Pretax Margin | 21.55% |
| Profit Margin | 14.44% |
| EBITDA Margin | 23.10% |
| EBIT Margin | 21.32% |
| FCF Margin | 10.45% |
Dividends & Yields
This stock pays an annual dividend of 1.20, which amounts to a dividend yield of 1.66%.
| Dividend Per Share | 1.20 |
| Dividend Yield | 1.66% |
| Dividend Growth (YoY) | 20.00% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 55.39% |
| FCF Payout Ratio | 76.48% |
| Buyback Yield | 0.12% |
| Shareholder Yield | 1.78% |
| Earnings Yield | 3.00% |
| FCF Yield | 2.17% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Pharmanutra is 95.67, which is 32.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 95.67 |
| Price Target Difference | 32.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 15.62% |
| EPS Growth Forecast (3Y) | 20.53% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharmanutra has an Altman Z-Score of 9.38 and a Piotroski F-Score of 5.
| Altman Z-Score | 9.38 |
| Piotroski F-Score | 5 |